IVC Industries sales rise 28.9% to $31.6 mil. in first quarter, paced by Fields of Nature.
This article was originally published in The Tan Sheet
Executive Summary
IVC INDUSTRIES SALES RISE 28.9% TO $31.6 MIL. IN FIRST QUARTER ended Oct. 31, paced by IVC's best-selling vitamins and supplements line, the Fields of Nature brand, the company reported Dec. 11. Fields of Nature posted revenues of "over 15%" of total sales or approximately $4.7 mil., up from about $2.9 mil. -- 12% of sales -- in the prior-year quarter. IVC is planning to extend the brand with more than a dozen new products early in 1997
You may also be interested in...
Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
EMA Set To Discuss Safety Of Ranitidine
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
Alvogen Aims To Be First On EU Pazopanib
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: